Preclinical Assessment of Engineered Immunoglobulins in Immune Humanized Mice - Brian Soper, Ph.D.

July 22, 2022

Preclinical Assessment of Engineered Immunoglobulins in Immune-humanized Mice Presented by Brian Soper, Ph.D. - Senior Scientific Engagement Manager, The Jackson Laboratory, Bar Harbor, USA Presented on 17 June 2022 in Heidelberg, Germany

Preclinical Assessment of Engineered Immunoglobulins in Immune Humanized Mice - Brian Soper, Ph.D.

PEGS EU 2023 - Translational Humanized Models for Immunotherapy Drug Development

Rapid In Vivo Evaluation of Immuno-Modulatory Therapies Using Hu-PBMC NSG™ Mice

The Application of Humanized Mice in Manipulation of Myeloid Cells - Dr. Ali Roghanian

In Vivo Platforms for Autoimmune Pharmacology: MS-EAE Capabilities

CRS Highlights for EU Symposium

CAR T studies with significantly delayed onset of GvHD

Potency of PD-1+CTLA-4 Bispecific or Combination in a Humanized Mouse Model

Of Mice and Men - FcRn Biology and Its Implications in a Therapeutic Perspective - Jan Terje Andersen, Ph.D.

Mouse Models of Coronavirus Infection

JAX Tech Talk Episode 51: Let’s Talk Accelerating Research with JAX’s GvHD Platform (Mar. 1, 2022)

NOD/scid IL-2Rγnull Mice Reconstituted with Peripheral Blood Mononuclear Cells of Crohn’s Disease

Studying Complex, Systemic Immune Responses in Humanized Mice

JAX Tech Talk Episode 49: Let’s Talk COVID Models - 2022 Updates (Feb. 1, 2022)

JAX Tech Talk Episode 44: Let's Talk Grants for Genetic Background’s Impact on Translatability (Oct. 5, 2021)

JAX Tech Talk Episode 43: Let’s Talk Assessing Efficacy of GvHD Therapeutics (Sept. 14, 2021)

GvHD Efficacy Study Fact Sheet

Important Considerations for Generating Genetic Humanized Mouse Models

Genetically Diverse Mouse Models for Every Stage of the Research Pipeline

JAX Antibody Development Summit - Dave Serreze

Using mice to unravel the mysteries of COVID-19 disease